IDXG OTC
Interpace Biosciences, Inc.
1W: -6.4%
1M: -17.2%
3M: -27.3%
YTD: +0.8%
1Y: +46.3%
3Y: +14.3%
5Y: -87.0%
$6.00
-0.39 (-6.10%)
Weekly Expected Move ±6.7%
$5
$6
$6
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships13
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-06-29
Earliest Filing
2024-10-15
Latest Filing
customer: 6
investor: 3
supplier: 2
acquirer: 1
partner: 1
Counterparties (Filed by IDXG)
13 relationshipsCompanies named in IDXG's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Interpace Biosciences, Inc. | IDXG | acquirer | Company issuing Series C Convertible Preferred Stock in exchange for Series B Shares | 2024-10-15 | View |
| 1315 Capital II, L.P. | — | investor | Preferred Stockholder exchanging Series B Shares for Series C Shares | 2024-10-15 | View |
| Ampersand 2018 Limited Partnership | — | investor | Preferred Stockholder exchanging Series B Shares for Series C Shares | 2024-10-15 | View |
| INTERPACE BIOSCIENCES, INC. | IDXG | customer | Parent borrower in the Second Amendment to Loan and Security Agreement | 2023-10-27 | View |
| INTERPACE DIAGNOSTICS CORPORATION | INTR | customer | Borrower in the Second Amendment to Loan and Security Agreement | 2023-10-27 | View |
| INTERPACE DIAGNOSTICS, LLC | INTR | customer | Borrower in the Second Amendment to Loan and Security Agreement | 2023-10-27 | View |
| INTERPACE PHARMA SOLUTIONS, INC. | INTR | customer | Borrower in the Second Amendment to Loan and Security Agreement | 2023-10-27 | View |
| Interpace Pharma Solutions, Inc. | INTR | supplier | Seller providing transitional shared services to Buyer | 2022-09-07 | View |
| Interpace Biosciences, Inc. | IDXG | supplier | Seller providing transitional shared services to Buyer | 2022-09-07 | View |
| Flagship Biosciences, Inc. | — | customer | Buyer purchasing assets and receiving transitional shared services from Seller | 2022-09-07 | View |
| Interpace Biosciences, Inc. | IDXG | partner | Company issuing the subordinated convertible promissory note | 2022-05-10 | View |
| BroadOak Fund V, L.P. | — | investor | Holder of the subordinated convertible promissory note | 2022-05-10 | View |
| Interpace Biosciences, Inc. | IDXG | customer | Borrower in a secured promissory note amendment | 2021-06-29 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-27 | Bylaws Amendment; Regulation FD; Exhibits | View | |
| 2026-08-26 | Officer/Director Change; Exhibits | View | |
| 2026-08-21 | Shareholder Vote | View | |
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-05-14 | Earnings Release; Exhibits | View | |
| 2026-04-01 | Earnings Release; Exhibits | View | |
| 2026-01-20 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-12-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-01 | Costs Associated with Exit or Disposal Activities; Other Events; Financial Statements and Exhibits | View | |
| 2025-03-06 | Non-Reliance on Previously Issued Financial Statements | View | |
| 2025-01-27 | Costs Associated with Exit or Disposal Activities; Other Events; Financial Statements and Exhibits | View | |
| 2025-01-21 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Costs Associated | Agreement | View |
| 2025-01-10 | Other Events; Financial Statements and Exhibits | View | |
| 2024-11-13 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-15 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Material Modifica | Agreement | View |
| 2024-08-02 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR